




# Annual Work Programme (AWP) 2021 Info day webinar

**GRANT MANAGEMENT**

13/07/2021

# The signed Grant Agreement as a basis



# Electronic management system

**RESEARCH & INNOVATION**  
Grant Management Services

European Commission

Help

Paola D'ACAPITO

Launch new interaction with the EU +

### MY PROJECT

Call: HP-JA-2019  
Type of Action: HP-PJ  
Acronym: Best-ReMaP  
Current Phase: Grant Management  
Number: 951202  
Duration: 36 months  
GA based on the: CHAFEA MGA - Multi - 2.1  
Start Date: 01 Oct 2020  
Estimated Project Cost: €7,500,000.00  
Requested EU Contribution: €6,000,000.00  
Contact: [Marilena DI STASI](#)

Latest Legal Data  
Active Processes  
Document Library  
Communication Centre  
Archived Processes

**H2020 ONLINE MANUAL**

**HOW TO**

#### Continuous Reporting

951202 - Best-ReMaP

01 Oct 2020

Started

Completed

Continuous reporting data

Process documents  
No documents.

Process communications

Process history

#### Proposal Management & Grant Preparation

951202 - Best-ReMaP

05 Nov 2019

Submitted Informed Invited Prepared Signed Paid

Expand All Collapse All

- Process documents
  - Evaluation Result Letter (1)
  - Evaluation Summary (1)
  - Grant Agreement (1)
  - Grant Declaration (24)
  - GrantData (1)
  - Inbound Notification (8)
  - Legal Supporting Document (External) (1)
  - Prefinancing (1)
  - Proposal (1)
- Process communications
- Process history

# Continuous Reporting

Grant Management Project Continuous Report

951202 (Best-ReMaP) HP-PJ

3rd Health Programme

Call: HP-JA-2019 Unit: CHAFAE/B

Topic: JA-01-2019

Summary for publication (Red X)

Deliverables Ethics, DMP, Other Reports (Info icon)

Milestones (Info icon)

Critical Risks (Green checkmark)

Publications (Red X)

Dissemination (Green checkmark)

Questionnaire (HP PX) (Green checkmark)

- Continuous update of summary for publication
- Uploading of deliverables
- Monitoring/reporting on milestones and critical risks
- Reporting on publications and dissemination

RESEARCH & INNOVATION Grant Management Services

European Commission

MY PROJECT

Call: HP-JA-2019 Type of Action: HP-PJ Acronym: Best-ReMaP

Continuous Reporting 951202 - Best-ReMaP

Continuous reporting data

01 Oct 2020 Started Completed

Launch new interaction with the EU

# Executive publishable summary

Used for dissemination purposes. Please include:

- Summary of the action context and objectives
- A description of the work performed and main results achieved
- A description of the expected final results and their potential impact and use (if possible beyond the duration of the project)

## **SPECIFICS**

Keep it up to date!

*"The project aims at...to achieve" shall become "The project aimed at...The project achieved ..."*

# Deliverables

Grant Management Project Continuous Report

51202 (Best-ReMaP) HP-PJ

3rd Health Programme

Call: HP-JA-2019 Unit: CHAFEA/B

Topic: JA-01-2019

Summary for publication ❌

**Deliverables Ethics, DMP, Other Reports** ⓘ

Milestones ⓘ

Critical Risks ✅

Publications ❌

Disseminat... ✅

Questionna... (HP PX) ✅

## Deliverables, Ethics, DMP, Other Reports

For each Deliverable, a single file (max 52MB) can be uploaded

Show Filters Clear Filters

WP No	Del Rel. Nr	Del No	Title	Description	Lead B	Nature	Disseminat	Est. Del. Date	Rev. Due Date	Receipt Date	Approval Date	Status
WP1	D1.1	D1	D1.1 Meeting minutes of the PDMF	Minuted discussions and conclusions of the poli... ⓘ	NIJZ	Report	Public	30 Sep 2021				Pending
WP1	D1.2	D2	D1.2 Meeting minutes of the PDMF	Minuted discussions and conclusions of the poli... ⓘ	NIJZ	Report	Public	30 Sep 2022				Pending
WP1	D1.3	D3	D1.3 Meeting minutes of the PDMF	Minuted discussions and conclusions of the poli... ⓘ	NIJZ	Report	Public	30 Sep 2023				Pending
WP2	D2.1	D4	MD.2.1 Introductory leaflet	This is a publication with core project informa... ⓘ	SU	Report	Public	31 Dec 2020				Pending
WP2	D2.2	D5	MD.2.2 Website	This website will provide project and WP level ... ⓘ	SU	Websites,	Public	31 Dec 2020				Pending
WP2	D2.3	D6	D2.3 Dissemination strategy	Strategy specifies the dissemination aims and o... ⓘ	SU	Report	Public	31 Jan 2021				Pending
WP2	D2.4	D7	MD2.4 Mid-term report on Dissemi	Data analytics driven analysis to answer the ke... ⓘ	SU	Report	Public	31 Mar 2022				Pending
WP2	D2.5	D8	D2.5 Promotional movies complet	Two short promotional films, out of which one w... ⓘ	SU	Websites,	Public	30 Sep 2023				Pending
WP2	D2.6	D9	MD2.6 Layman version of the final	This is a short, 4 pages version of the final r... ⓘ	SU	Report	Public	30 Sep 2023				Pending
WP2	D2.7	D10	MD2.7 Final report on Disseminati	Data analytics driven analysis, making the fina... ⓘ	SU	Report	Public	30 Sep 2023				Pending
WP3	D3.1	D11	D3.1 Evaluation strategy	Preparation and publication of the evaluation s... ⓘ	THL	Report	Public	28 Feb 2021				Pending
WP3	D3.2	D12	MD2.3 Mid-term report on Evaluat	Report on the progress, processes and outcomes,... ⓘ	THL	Report	Public	31 Mar 2022				Pending
WP3	D3.3	D13	MD3.3 Final Evaluation report	The final evaluation report outlining the centr... ⓘ	THL	Report	Public	30 Sep 2023				Pending
WP4	D4.1	D14	D4.1 Documents retrieved in the c	Summary of the conclusions and recommendations ... ⓘ	ISS	Report	Public	31 Mar 2021				Pending
WP4	D4.2	D15	MD4.2 Integration and sustainabili	This report will include a proposed plan descri... ⓘ	ISS	Report	Public	30 Sep 2023				Pending



# Deliverables

- Files per deliverable: **1 only!**
- Format: .pdf, .zip file
- Size: up to 52 MB
- Standard cover page: strongly recommended
- Executive summary and/or user guide: strongly recommended
- GDPR and pre-existing rights: **to be fully respected**
- Application of Article 22: **mandatory**



# Milestones

Grant Management Project Continuous Report

051202 (Best-ReMaP) HP-PJ

3rd Health Programme

Call: HP-JA-2019 Unit: CHAFAE/B

Topic: JA-01-2019

Summary for publication

Deliverables Ethics, DMP, Other Reports

**Milestones**

Critical Risks

Publications

Disseminat...

Questionna... (HP PX)



## Milestones

Number	Name	Lead Beneficiary	Delivery Date (Annex I)	Achieved	Delivery Date (actual)	Comments
1	M 1.1 Best-ReMaP Kick-off Meeting - SC	NIJZ	31 Oct 2020	<input type="checkbox"/>		
2	M 1.2 Finalised Best-ReMaP Project Poli	NIJZ	31 Jan 2021	<input type="checkbox"/>		
3	M 1.3 Signature of Best-ReMaP consorti	NIJZ	31 Mar 2021	<input type="checkbox"/>		
4	M 1.4 Mid-term conference executed	NIJZ	30 Nov 2021	<input type="checkbox"/>		
5	M1.5 Delivery of the Interim Report	NIJZ	31 Mar 2022	<input type="checkbox"/>		
6	M1.6 Final conference executed	NIJZ	30 Sep 2023	<input type="checkbox"/>		
7	M1.7 Final Report	NIJZ	30 Sep 2023	<input type="checkbox"/>		
8	M2.1 6th Newsletter issued	SU	31 Aug 2023	<input type="checkbox"/>		
9	M2.2 Webinars to disseminate WP resul	SU	30 Sep 2023	<input type="checkbox"/>		
10	M3.1 Selection of external evaluators	THL	31 Oct 2020	<input type="checkbox"/>		
11	M3.2 First meeting with the external ev	THL	31 Jan 2021	<input type="checkbox"/>		
12	M3.3 Completed outcome evaluation w	THL	30 Sep 2023	<input type="checkbox"/>		
13	M4.1 At least 6 semi-structured intervie	ISS	30 Sep 2021	<input type="checkbox"/>		
14	M4.1 At least 3 semi-structured intervie	ISS	31 Mar 2022	<input type="checkbox"/>		
15	M4.3 JRC implements food database	ISS	31 Jul 2023	<input type="checkbox"/>		
16	M4.4 Policy dialogues completed	ISS	30 Sep 2023	<input type="checkbox"/>		
17	M5.1 Dissemination workshop on 1st sni	ANSES	31 Oct 2020	<input type="checkbox"/>		





# Critical risks

Grant Management Project Continuous Report

51202 (Best-ReMaP) HP-PJ

3rd Health Programme

Call: HP-JA-2019 Unit: CHA/EA/B

Summary for publication

Deliverables Ethics, DMP, Other Reports

Milestones

Critical Risks

Publications

Disseminat...

Questionna... (HP PX)



## Critical Risks

### Foreseen Risks (Annex-I)

Number	Description	Work Package No.	Risk Mitigation Measures	State of the Play Reference Reporting Period	State of the Play Mitigation Measures Applied	State of the Play Risk Materialized	State of the Play Com...
1	WP 1 - mgmt. and meeting structure do not fulfil the anticipated objectives.	1	AVOID: WP 1 will work together with WP 3 to evaluate the mgmt. and meeting structure t				
2	WP 1 - Associated Partners could be passive in communication with the Project Managem	1	AVOID: A detailed mailing list of contact persons will be put in place with at least 5+ conta				
3	WP 1 - Associated Partners and WPL will not submit necessary reporting materials on time	1	AVOID: Preparation for the interim and financial reports will begin at least 2 months before				
4	WP 1 - Associated Partners will not adhere to planned budget and will under or over spend	1	AVOID: Regular 6 monthly reports will be gathered by the PMT to monitor financial expend				
5	WP 1 - Associated Partners will not fulfil their planned obligations, will not deliver plann	1	AVOID: Deliverables will be tracked by each WPL and by the PMT, who will discuss the stat				
6	WP 1 - COVID-19 epidemic to impact successful implementation of the JA	1	AVOID: The JA faces a volatile situation regarding potential future waves of the COVID-19				
7	WP2 - Some core topics of the JA may prove to be highly sensitive and even political issue	2	AVOID: The content of such communication as well as the communication channels will be				
8	WP2 - Associated Partners will not be active in disseminating Best - ReMaP content in local	2	AVOID: Local Stakeholder Forums have been planned as a mandatory activity for each Cor				
9	WP2 - Partners may not be active in notifying Dissemination Team of content for the news	2	AVOID: The Dissemination Team will be in constant contact with the PMT and WPLs and wi				
10	WP 2- Specific stakeholders may be unsatisfied with their level of inclusion in the JA or wi	2	AVOID: Different events will be tailored to different groups of stakeholders in order to eff				

### Unforeseen Risks

There are no unforeseen critical risks.

Foreseen Risks (Risk analysis) – to be documented with corresponding mitigation actions

Unforeseen Risks – to be added and documented, when occurring, with corresponding mitigation actions

# Thank you



© European Union 2020

Unless otherwise noted the reuse of this presentation is authorised under the [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.

Slide xx: [element concerned](#), source: [e.g. Fotolia.com](#); Slide xx: [element concerned](#), source: [e.g. iStock.com](#)